All In Biotech

Drug Trial Radar · NCT07938411

A Study to Assess the Effect of Pacibekitug on Major Cardiovascular Events in Patients After a Myocardial Infarction

A Randomized, Double-blind, Placebo-controlled, Multi-center Trial Assessing the Effect of Pacibekitug on Major Cardiovascular Events in Participants After a Myocardial Infarction and at High Cardiovascular Risk (PINNACLE-MI)

Last checked: Nov 19, 2026Latest source record: Nov 16, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruitingPivotal-lookingPhase 3. Randomized with 10,000 participants. This is a heuristic, not a regulatory label.

Status

Not yet recruiting

Enrollment

10,000

Planned (sponsor's estimate)

Start

Nov 30, 2026

Primary completion

Oct 22, 2030

Study completion Oct 22, 2030

Sponsor

Lead sponsor
Novartis PharmaceuticalsNovartis (NVS)
Sponsor type
Industry
First posted
Nov 16, 2026

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The main purpose of this study is to demonstrate the superiority of pacibekitug compared to placebo in reducing the risk of 3-point coronary major adverse cardiovascular events (3P-Coronary- MACE), defined as a composite of coronary heart disease (CHD) death, non-fatal myocardial infarction (MI), and urgent coronary revascularization, in participants after an MI, at high cardiovascular (CV) risk and receiving standard of care (SoC) secondary CV prevention therapies.

Conditions

  • Myocardial Infarction

Interventions

  • PacibekitugDrug

    pacibekitug s.c.

  • PlaceboDrug

    Placebo s.c.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Time to the first occurrence of 3P-Coronary-MACETime frame: Up tp 1398 days

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.